Cardiogenic shock and cardiac arrest complicating ST-segment elevation myocardial infarction in the United States,

Saraschandra Vallabhajosyula1, Shannon M Dunlay2, Abhiram Prasad3

  • 1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, United States; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, United States; Center for Clinical and Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States; Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States.

Resuscitation
|August 7, 2020
PubMed

Insights

Cardiogenic shock and cardiac arrest complicating ST-elevation myocardial infarction (STEMI) have increased. The combination of both conditions significantly raises in-hospital mortality and organ failure rates in STEMI patients.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Health Services Research

Background:

  • Limited data exist on the outcomes of cardiogenic shock (CS) and cardiac arrest (CA) in ST-elevation myocardial infarction (STEMI).
  • Understanding these outcomes is crucial for improving patient care and resource allocation.

Purpose of the Study:

  • To analyze temporal trends and outcomes of STEMI admissions complicated by CS and/or CA.
  • To compare in-hospital mortality, hospitalization costs, and utilization of palliative care and DNR status across different STEMI complication cohorts.

Main Methods:

  • Retrospective analysis of adult STEMI admissions (2000-2017) from the National Inpatient Sample.
  • Classification of STEMI admissions into four groups: CS+CA, CS only, CA only, and no CS/CA.
  • Comparison of temporal trends, mortality, costs, DNR status, and palliative care referrals.

Main Results:

  • STEMI admissions with CS, CA, or both significantly increased from 2000 to 2017.
  • The CS+CA cohort exhibited higher rates of multiorgan failure (77.2%) compared to CS only (59.7%) and CA only (26.3%).
  • In-hospital mortality was substantially higher in the CS+CA group (aOR 18.37) compared to other cohorts.

Conclusions:

  • The combination of CS and CA in STEMI patients is associated with significantly higher rates of non-cardiac organ failure and in-hospital mortality.
  • These findings highlight the critical impact of combined CS and CA on STEMI outcomes.
  • Further research and clinical strategies are needed to address the high burden of these complex cases.
Abstract

Related Concept Videos

Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
232
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
513
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
347
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
276
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
122
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
136